Form 4: Xenetic Biosciences Interim CEO Acquires Stock Options

James Parslow, Interim CEO and CFO of Xenetic Biosciences, acquired 20,000 stock options on June 18, 2024.

Summary

• James Parslow, the Interim CEO and CFO of Xenetic Biosciences, Inc. (XBIO), reported a transaction involving the acquisition of derivative securities.
• On June 18, 2024, Parslow acquired 20,000 stock options with an exercise price of $3.99.
• These options vest over a three-year period, with one-fourth vesting immediately and the remainder vesting annually on June 18 until 2027.
• The options expire on June 18, 2034.
• Following the transaction, Parslow directly owns 20,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The vesting schedule is a positive sign, but the overall impact is likely minimal.

Positives

• The acquisition of stock options by the Interim CEO and CFO could align his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the stock option grant as a way to align management's interests with the company's long-term success.

Key Dates

Keywords

stock options, Xenetic Biosciences, XBIO, Form 4, James Parslow, Interim CEO, CFO, derivative securities, beneficial ownership